Circulating Nucleic Acids in Plasma/Serum and Tumor Progression: Are Apoptotic Bodies Involved? An Experimental Study in a Rat Cancer Model

2006 ◽  
Vol 1075 (1) ◽  
pp. 165-173 ◽  
Author(s):  
J. SAMOS ◽  
D. C GARCIA-OLMO ◽  
M. G PICAZO ◽  
A. RUBIO-VITALLER ◽  
D. GARCIA-OLMO
Keyword(s):  
Experimental Study ◽  
Nucleic Acids ◽  
Tumor Progression ◽  
Apoptotic Bodies ◽  
Cancer Model ◽  
Circulating Nucleic Acids

scholarly journals Novel Epigenetic Biomarkers in Pregnancy-Related Disorders and Cancers

Cells ◽  
2019 ◽  
Vol 8 (11) ◽  
pp. 1459 ◽  
Author(s):  
Karin-Kujundzic ◽  
Sola ◽  
Predavec ◽  
Potkonjak ◽  
Somen ◽  
...  
Keyword(s):  
Nucleic Acids ◽  
Extracellular Vesicles ◽  
Diagnostic Tools ◽  
Epigenetic Changes ◽  
Apoptotic Bodies ◽  
Diagnostic Biomarkers ◽  
Epigenetic Biomarkers ◽  
Circulating Nucleic Acids ◽  
Specific Proteins ◽  
In Pregnancy

As the majority of cancers and gestational diseases are prognostically stage- and grade-dependent, the ultimate goal of ongoing studies in precision medicine is to provide early and timely diagnosis of such disorders. These studies have enabled the development of various new diagnostic biomarkers, such as free circulating nucleic acids, and detection of their epigenetic changes. Recently, extracellular vesicles including exosomes, microvesicles, oncosomes, and apoptotic bodies have been recognized as powerful diagnostic tools. Extracellular vesicles carry specific proteins, lipids, DNAs, mRNAs, and miRNAs of the cells that produced them, thus reflecting the function of these cells. It is believed that exosomes, in particular, may be the optimal biomarkers of pathological pregnancies and cancers, especially those that are frequently diagnosed at an advanced stage, such as ovarian cancer. In the present review, we survey and critically appraise novel epigenetic biomarkers related to free circulating nucleic acids and extracellular vesicles, focusing especially on their status in trophoblasts (pregnancy) and neoplastic cells (cancers).

The impact of non-tumor-derived circulating nucleic acids implicates the prognosis of non-small cell lung cancer

2012 ◽  
Vol 139 (1) ◽  
pp. 67-76 ◽  
Author(s):  
Chanida Vinayanuwattikun ◽  
Pakorn Winayanuwattikun ◽  
Poonchavist Chantranuwat ◽  
Apiwat Mutirangura ◽  
Virote Sriuranpong
Keyword(s):  
Lung Cancer ◽  
Nucleic Acids ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Circulating Nucleic Acids ◽  
The Impact

Free circulating nucleic acids in plasma and serum as a novel approach to the use of internal controls in real time PCR based detection

2014 ◽  
Vol 207 ◽  
pp. 133-137 ◽  
Author(s):  
Ersin Karataylı ◽  
Yasemin Çelik Altunoğlu ◽  
Senem Ceren Karataylı ◽  
Cihan Yurdaydın ◽  
A. Mithat Bozdayı
Keyword(s):  
Nucleic Acids ◽  
Real Time ◽  
Real Time Pcr ◽  
Internal Controls ◽  
Circulating Nucleic Acids ◽  
Novel Approach

Maternal Circulating Nucleic Acids as Markers of Placental Health

2018 ◽  
pp. 333-351
Author(s):  
Francesca Gaccioli ◽  
D. Stephen Charnock-Jones ◽  
Gordon C.S. Smith
Keyword(s):  
Nucleic Acids ◽  
Circulating Nucleic Acids

scholarly journals Plasma Nucleic Acids in the Diagnosis and Management of Malignant Disease

2002 ◽  
Vol 48 (8) ◽  
pp. 1186-1193 ◽  
Author(s):  
Philip J Johnson ◽  
YM Dennis Lo
Keyword(s):  
Nucleic Acid ◽  
Nucleic Acids ◽  
Clinical Importance ◽  
Barr Virus ◽  
Circulating Nucleic Acids ◽  
Clinical Relationship ◽  
Malignant State ◽  
Cancer Types ◽  
Epstein Barr ◽  
Near Future

Abstract Background: There is a need for development of molecular markers of cancer that can be used clinically for the detection, prognostication, and monitoring of cancer. Recently, there has been much interest in the potential use of nucleic acid markers in plasma and serum for this purpose. Approach: We reviewed published literature up to 2002 on the topic, with a particular emphasis on reports published between 1996 and 2002. Content: The nucleic acid markers described in plasma and serum include oncogene mutations/amplifications, microsatellite alterations, and gene rearrangements. Such markers have been described in many cancer types, including lung, colon, and breast. Epigenetic alterations, such as aberrant promoter methylation, have been identified in plasma and serum. Viral nucleic acid markers, such as Epstein–Barr virus DNA in plasma and serum, are reviewed in detail with regard to their application to virus-associated cancers such as nasopharyngeal carcinoma and various lymphomas. More recently, mitochondrial DNA and tumor-related mRNAs have been identified in plasma and serum from patients with several types of tumors. Conclusions: Circulating nucleic acids are an emerging class of molecular tumor markers. Their wide applicability and clinical relationship with the malignant state will likely grant them increasing clinical importance in the near future.

Circulating Nucleic Acids (RNA/DNA) in Breast Cancer

2016 ◽  
pp. 235-256
Author(s):  
Isabelle Gingras ◽  
Libero Santarpia ◽  
Michail Ignatiadis
Keyword(s):  
Breast Cancer ◽  
Nucleic Acids ◽  
Circulating Nucleic Acids
Sign in / Sign up

Export Citation Format

Share Document